

Attorney Document No. MBP-005XX  
Filed: Herewith  
Group Art Unit:

The Examiner is encouraged to telephone the undersigned attorney to discuss any matter which would expedite allowance of the present application.

Respectfully submitted,

KERSTIN KRIEGELSTEIN

By: 

Charles L. Gagnebin III  
Registration No. 25,467  
Attorney for Applicant

WEINGARTEN, SCHURGIN, GAGNEBIN  
& HAYES LLP

Ten Post Office Square  
Boston, MA 02109

Telephone: (617) 542-2290  
Telecopier: (617) 451-0313

Date: 3-2-1

CLG/jde/243729

2008 MAR 26 PM 4:00

MARKED-UP VERSION OF AMENDED CLAIMS TO IPER

1 3. Use according to claim 1 ~~or 2~~, wherein said disorder is a  
2 peripheral and/or CNS-disorder.

1 7. The pharmaceutical composition according to claim 5 ~~or 6~~,  
2 wherein said compound is an antibody directed to TGF- $\beta$  or a  
3 compound having the binding site of a TGF- $\beta$  receptor.

1 8. The pharmaceutical composition according to ~~anyone of~~  
2 ~~claims 5 to 7~~ claim 5, wherein said second compound is selected  
3 from the group consisting of urokinase and tissue plasminogen  
4 activator.